Search results for "LK"

showing 10 items of 8438 documents

Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide

2009

Purpose To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma. Patients and Methods A total of 41 adult patients (median Karnofsky performance status, 90%; median age, 56 years) were treated with preirradiation TMZ at 150 mg/m 2 (1 week on/1 week off), involved-field radiotherapy combined with concomitant low-dose TMZ (50 mg/m 2 ), maintenance TMZ starting at 150 mg/m 2 using a 1-week on/1-week off schedule, plus maintenance indomethacin (25 mg twice daily). Results The median follow-up interval was 21.7 months. Grade 4 hematologic toxicit…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentIndomethacinDisease-Free SurvivalDrug Administration ScheduleGermanyInternal medicineConfidence IntervalsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesKarnofsky Performance StatusAntineoplastic Agents AlkylatingDNA Modification MethylasesSurvival rateAgedChemotherapyRadiationTemozolomideBrain Neoplasmsbusiness.industryTumor Suppressor ProteinsAnti-Inflammatory Agents Non-SteroidalDNA MethylationMiddle AgedCombined Modality TherapyConfidence intervalSurgeryDacarbazineSurvival RateRegimenDNA Repair EnzymesOncologyConcomitantToxicityFemaleGlioblastomabusinessChemoradiotherapyFollow-Up Studiesmedicine.drugInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin

2017

<b><i>Objectives:</i></b> Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, in patients with soft-tissue sarcoma (STS). We evaluated the role of BMI as a risk factor for trabectedin-related toxicity in patients with STS. <b><i>Methods:</i></b> Data from 51 patients with metastatic/advanced STS treated with trabectedin after progression on ≥1 anthracycline ± ifosfamide regimen were retrospe…

AdultMaleOncologySarcopeniaCancer Researchmedicine.medical_specialtyNeutropeniaDioxolesNeutropeniaBody Mass Index03 medical and health sciences0302 clinical medicineThinnessRisk FactorsTetrahydroisoquinolinesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesIfosfamide030212 general & internal medicineRisk factorAntineoplastic Agents AlkylatingTrabectedinAgedRetrospective StudiesAged 80 and overIfosfamideToxicitybusiness.industrySoft tissue sarcomanutritional and metabolic diseasesSarcomaGeneral MedicineMiddle Agedmedicine.diseaseOncology030220 oncology & carcinogenesisSoft-tissue sarcomaFemaleUnderweightmedicine.symptombusinessBody mass indexFebrile neutropeniaTrabectedinmedicine.drugOncology
researchProduct

MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers

2013

The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear. Here, we report on a retrospective study of 47 patients with either newly diagnosed (30 patients) or recurrent (17 patients) glioblastoma (WHO grade IV) treated with BCNU (bis-chloroethylnitrosourea) wafers. Thirteen of the newly diagnosed patients received local BCNU and irradiation only (first-line BCNU), while 17 patients additionally received concomitant and adjuvant temozolomide (TMZ) radiochemotherapy (first-line BCNU + TMZ). Of the 17 patients treated for recurrent glioblastoma (second-line BCNU), 16 had rec…

AdultMaleOncologymedicine.medical_specialtyMethyltransferaseDacarbazineDisease-Free SurvivalO(6)-Methylguanine-DNA Methyltransferase03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsTemozolomidemedicineHumansKarnofsky Performance StatusPromoter Regions GeneticAntineoplastic Agents AlkylatingSurvival analysisAgedRetrospective StudiesCarmustineTemozolomideBrain Neoplasmsbusiness.industryO-6-methylguanine-DNA methyltransferaseChemoradiotherapyGeneral MedicineDNA MethylationMiddle AgedPrognosisCarmustineCombined Modality TherapySurvival Analysis3. Good healthSurgeryDacarbazine030220 oncology & carcinogenesisConcomitantFemaleSurgeryNeurology (clinical)Glioblastomabusiness030217 neurology & neurosurgeryChemoradiotherapymedicine.drugBritish Journal of Neurosurgery
researchProduct

PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy

2012

Soft tissue sarcomas are aggressive tumors representing <1% of all adult neoplasms. Aim of our study was to evaluate promyelocytic leukemia gene expression value as prognostic factor and as a factor predicting response to alkylating agents/antracycline-based first line therapy. One hundred eleven patients affected by locally advanced and metastatic soft tissue sarcoma were selected. PML expression was evaluated by immunohistochemical analysis in pathological samples and in the corresponding normal tissue from each case. PML immunohistochemical results were correlated with prognosis and with radiological response to alkylating agents/antracycline-based first line therapy. PML expression was …

AdultMaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical BiochemistryCellDown-RegulationSoft Tissue NeoplasmsPromyelocytic Leukemia ProteinLiposarcomaPleomorphic LiposarcomaYoung AdultPredictive Value of TestsInternal medicinemedicineHumansAnthracyclinesAntineoplastic Agents AlkylatingPathologicalAgedRetrospective StudiesAged 80 and overPMLbusiness.industryTumor Suppressor ProteinsSoft tissue sarcomaNuclear ProteinsSoft tissueSarcomaCell BiologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistrymedicine.anatomical_structuresoft tissue sarcomas; PMLDrug Resistance Neoplasmsoft tissue sarcomaImmunologyImmunohistochemistryFemaleSarcomabusinessTranscription Factors
researchProduct

Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases.

2010

Abstract Background/Aim Plasma cells infiltrate in the liver is a prototype lesion of autoimmune liver diseases. The possible role of plasma cells isotyping (IgM and IgG) in the liver in the diagnostic definition of autoimmune liver disease, and particularly in variant syndromes such as autoimmune cholangitis and the primary biliary cirrhosis/autoimmune hepatitis overlap syndrome, is less defined. Methods We analysed the clinical, serological and histological features of 83 patients with autoimmune liver disease (40 primary biliary cirrhosis, 20 autoimmune hepatitis, 13 primary sclerosing cholangitis, 4 autoimmune cholangitis and 6 overlap syndrome) compared to 34 patients with chronic hepa…

AdultMalePathologymedicine.medical_specialtyLiver kidney microsomal type 1 antibodyCholangitisBiopsyCholangitis SclerosingPlasma CellsAutoimmune hepatitisAutoimmune cholangitis Autoimmune hepatitis IgG plasma cells IgM plasma cells Immunostaining Liver biopsy Overlap syndromes Portal infiltrate Primary biliary cirrhosisSettore MED/08 - Anatomia PatologicaAutoimmune DiseasesPrimary sclerosing cholangitisSex FactorsPrimary biliary cirrhosismedicineHumansAgedAutoantibodiesHepatitisSettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testLiver Cirrhosis Biliarybusiness.industryGastroenterologyAlanine TransaminaseOverlap syndromegamma-GlutamyltransferaseMiddle AgedAlkaline Phosphatasemedicine.diseaseHepatitis CHepatitis AutoimmuneImmunoglobulin MLiverImmunoglobulin GLiver biopsyFemaleBile DuctsbusinessAnti-mitochondrial antibody
researchProduct

Food-related sensory experience from birth through weaning: contrasted patterns in two nearby European regions

2007

International audience; This study describes infant feeding practices among mothers from two European regions from the perspective of early sensory experiences. Two groups of mothers, one in Dijon , France (n=139), the other in Aalen , Germany (n=157) with infants aged 4–9 months were interviewed using a structured questionnaire. Clear between- and within-group differences in weaning practices were found, particularly with respect to breastfeeding duration (Aalen>Dijon) and exposure to flavour variety early in weaning (Dijon>Aalen). By 4 months, 65% of infants in Dijon and 20% in Aalen, had received their first non-milk, solid foods. Before beginning to wean, 39% of mothers in Dijon offered…

AdultMalePediatricsmedicine.medical_specialty030309 nutrition & dieteticsVARIETYEARLY EXPERIENCEBreastfeedingEUROPEAN REGIONSSensationWeaningBreast milk03 medical and health sciencesFood Preferences0302 clinical medicineFeeding behaviorFLAVOUR PERCEPTIONGermanySurveys and QuestionnairesVegetablesmedicineWeaningHumans030212 general & internal medicineInfant feedingGeneral PsychologyComputingMilieux_MISCELLANEOUS2. Zero hunger0303 health sciencesNutrition and Dieteticsbusiness.industry[SCCO.NEUR]Cognitive science/NeuroscienceBREASTFEEDINGInfantBreast FeedingNON-MILK FOODSSolid foodTaste[ SCCO.NEUR ] Cognitive science/NeuroscienceFemaleInfant FoodFrancebusinessBreast feeding[SDV.AEN]Life Sciences [q-bio]/Food and NutritionDemography
researchProduct

Everyday Life, Dietary Practices, and Health Conditions of Adult PKU Patients: A Multicenter, Cross-Sectional Study

2020

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Only few data on dietary management of adult phenylketonuria (PKU) patients are published. &lt;b&gt;&lt;i&gt;Objectives:&lt;/i&gt;&lt;/b&gt; This study aimed to assess living situation, dietary practices, and health conditions of early-treated adult PKU patients. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; A total of 183 early-treated PKU patients ≥18 years from 8 German metabolic centers received access to an online survey, containing 91 questions on sociodemographic data, dietary habits, and health conditions. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; 144/183 patients (66% females) completed the questionnaire. Compared with German …

AdultMalePediatricsmedicine.medical_specialtyAdolescentCross-sectional studyHealth StatusPhenylalanineMedicine (miscellaneous)Living situationProfessional statusYoung AdultQuality of lifePhenylketonuriasSurveys and QuestionnairesActivities of Daily LivingDiet Protein-RestrictedPrevalenceHumansChildbirthMedicineAmino acid intakeAmino AcidsEveryday lifeNutrition and DieteticsDepressionbusiness.industryDietary managementFeeding BehaviorMiddle AgedCross-Sectional StudiesDietary SupplementsQuality of LifePatient ComplianceFemalebusinessAnnals of Nutrition and Metabolism
researchProduct

Safety of potential breast milk exposure to IFN-β or glatiramer acetate

2019

ObjectiveTo determine whether potential breast milk exposure to interferon-beta (IFN-β) or glatiramer acetate (GA) is safe for the infant.MethodsWe identified 74 infants born to 69 women with MS who breastfed under IFN-β (n = 39), GA (n = 34), or both (n = 1). Women had been enrolled into the German Multiple Sclerosis and Pregnancy Registry during pregnancy. Data were obtained from standardized, telephone-administered questionnaires completed by the mother during pregnancy and at 1, 3, 6, and 12 months postpartum and the infant's take-home medical record.ResultsThe median duration of exposed breastfeeding was 8.5 months (wide interquartile range: 4.9–12.7 months). Physical growth curves dur…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosis41BreastfeedingBreast milkArticleChild DevelopmentPregnancyInterquartile rangemedicineHumansImmunologic FactorsRegistriesGlatiramer acetatePregnancyMilk Humanbusiness.industryPostpartum PeriodInfantGlatiramer AcetateInterferon-betamedicine.disease54Pregnancy ComplicationsBreast FeedingNeurologyFemaleMedian bodyNeurology (clinical)businessBreast feedingPostpartum periodmedicine.drugNeurology - Neuroimmunology Neuroinflammation
researchProduct

One-year persistence of individual gait patterns identified in a follow-up study – A call for individualised diagnose and therapy

2017

Abstract Although a hunch about the individuality of human movements generally exists, differences in gait patterns between individuals are often neglected. To date, only a few studies distinguished individual gait patterns in terms of uniqueness and emphasised the relevance of individualised diagnoses and therapy. However, small sample sizes have been a limitation on identifying subjects based on gait patterns, and little is known about the permanence of subject-specific characteristics over time. The purpose of this study was (1) to prove the uniqueness of individual gait patterns within a larger sample and (2) to prove the long-term permanence of individual gait patterns. A sample of 128…

AdultMalePersistence (psychology)medicine.medical_specialtyBiophysicsSample (statistics)Barefoot03 medical and health sciences0302 clinical medicineGait (human)Physical medicine and rehabilitationmedicineHumansOrthopedics and Sports MedicineForce platformMedical diagnosisGround reaction forceGaitRehabilitation030229 sport sciencesHealthy VolunteersBiomechanical PhenomenaPreferred walking speedBiological Variation PopulationFemalePsychologyhuman activitiesSocial psychology030217 neurology & neurosurgeryFollow-Up StudiesGait &amp; Posture
researchProduct

Metabolic Evaluation of 94 Patients 5 to 16 Years After Ileocecal Pouch (Mainz Pouch 1) Continent Urinary Diversion

2003

PURPOSE In continent urinary diversion metabolic disturbances may be encountered in long-term followup. We evaluated metabolic consequences in patients with a minimum followup of 5 years after Mainz pouch 1 urinary diversion.At our institution continent urinary diversion using the ileocecal segment was performed between 1983 and 1995 in 458 patients. A total of 94 patients with an ileocecal pouch for a minimum of 5 years were reevaluated for metabolic changes. Median followup was 9.0 years. Routine laboratory parameters, blood gas analysis, vitamin B12, vitamin D25, cross-laps, bone specific alkaline phosphatase, osteocalcin and propeptide of type I collagen were obtained. Bone density was …

AdultMalePhosphopeptidesmedicine.medical_specialtyBone diseaseBone densityUrologymedicine.medical_treatmentUrinary systemOsteocalcinOsteoporosisSodium CitratePostoperative ComplicationsCalcitriolBone DensityReference ValuesPotassium CitrateHumansMedicineCitratesMegaloblastic anemiaAgedbusiness.industryUrinary Reservoirs ContinentUrinary diversionMiddle AgedAlkaline Phosphatasemedicine.diseaseSurgeryVitamin B 12FemaleCollagenBlood Gas AnalysisPouchAcidosisEnergy MetabolismbusinessContinent Urinary DiversionProcollagenFollow-Up StudiesJournal of Urology
researchProduct